PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.15%
R&D growth while TRAW reduces spending. John Neff would investigate strategic advantage.
3110.63%
G&A change of 3110.63% while TRAW maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11227.11%
Operating expenses growth while TRAW reduces costs. John Neff would investigate differences.
11227.11%
Total costs growth while TRAW reduces costs. John Neff would investigate differences.
26362.71%
Interest expense growth above 1.5x TRAW's 995.24%. Michael Burry would check for over-leverage.
-84.19%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-40.83%
EBITDA decline while TRAW shows 33.56% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-9873.13%
Operating income decline while TRAW shows 23.59% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-850.18%
Other expenses reduction while TRAW shows 961.80% growth. Joel Greenblatt would examine advantage.
-16129.65%
Pre-tax income decline while TRAW shows 31.33% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
155593.20%
Tax expense change of 155593.20% while TRAW maintains burden. Bruce Berkowitz would investigate strategy.
-16129.65%
Net income decline while TRAW shows 31.33% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-12933.18%
EPS decline while TRAW shows 30.65% growth. Joel Greenblatt would examine position.
-12933.18%
Diluted EPS decline while TRAW shows 30.65% growth. Joel Greenblatt would examine position.
24.22%
Share count change of 24.22% while TRAW is stable. Bruce Berkowitz would verify approach.
24.22%
Diluted share change of 24.22% while TRAW is stable. Bruce Berkowitz would verify approach.